TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a randomized controlled trial led by the University of Surrey, 61 participants took NOVOS Core or a placebo daily for six months. The supplement group showed favorable changes in endothelial function, arterial stiffness and systolic blood pressure; the trial measured biomarkers, not heart attacks, strokes or other clinical outcomes.
A University of Surrey-led randomized controlled trial found that participants taking the multi-component supplement NOVOS Core had favorable changes in endothelial function, arterial stiffness and systolic blood pressure after six months, compared with a placebo group. The 61-person study measured cardiovascular health biomarkers, not clinical outcomes such as heart attacks or strokes, so it does not establish that the supplement prevents cardiovascular disease.
The study assigned 33 participants to the supplement and 28 to a placebo, taken once daily for six months. Researchers also reported a change in blood vessel function and systolic blood pressure within an hour of the first dose. The reported findings come from a trial of limited size and duration.
At six months, the adjusted difference between groups in systolic blood pressure was 6.1 mmHg, favoring the supplement group. Pulse wave velocity, a measure of arterial stiffness, was also lower, with an adjusted between-group difference of 1.18 m/s. Flow-mediated dilation, which assesses how blood vessels respond to increased blood flow, improved in the supplement group relative to the control group.
Blood tests showed no significant changes in cholesterol or other blood lipids, according to the report. Researchers said the estimated 10-year cardiovascular risk fell modestly, largely reflecting the blood pressure difference. That estimate is not the same as observing fewer cardiovascular events, and the study was not designed to measure whether participants experienced them.
What the Vascular Measures Show
The results provide early human evidence that a supplement targeting several processes associated with aging may affect more than one vascular health marker. Blood pressure, endothelial function and arterial stiffness capture different aspects of blood vessel health and are associated with cardiovascular risk. Seeing changes across these measures may help researchers decide what to test in larger studies.
The size of the blood pressure difference should be interpreted with care. The report notes that previous large studies have associated a sustained 5 mmHg reduction in systolic pressure with about a 10% reduction in major cardiovascular events. That comparison is background from other research; it is not an outcome demonstrated by this six-month supplement trial. Whether the reported changes persist, and whether they translate into health benefits, remains unknown.
Products Worth Considering
Levoit Core 600S-P Smart Air Purifier for Large Rooms up to 2933 ft²
Levoit Vital 100S-P Air Purifier for Home and Pets
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
Aging Biology Tested in a Trial
The formulation combines vitamins and minerals, amino acids, and plant-derived bioactives selected for their relevance to multiple biological processes linked to aging. The trial tested the general proposition that addressing several such processes at once could affect cardiovascular biomarkers. It did not establish which ingredient, combination or biological mechanism accounted for the results.
The findings were published in European Heart Journal Open in a paper by Piercy and colleagues titled “Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial.” University of Surrey researchers described the work as an early test of the idea in people, with biomarkers chosen in place of clinical endpoints.
“We now need larger studies to understand the mechanisms involved and, importantly, whether these changes translate into longer-term health benefits.”
— Professor Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey
Questions Beyond the Six-Month Trial
The trial involved 61 participants and lasted six months. The supplied report does not provide enough detail to assess how broadly the findings apply to people with different health conditions, ages or medication use. It also does not establish whether changes continue after participants stop taking the supplement.
Researchers have not shown that the findings reduce heart attacks, strokes, deaths or other clinical outcomes. The contribution of individual ingredients, the mechanisms behind the measured changes, and the supplement’s longer-term effects also remain unclear. The reported blood pressure comparison with prior research should not be read as evidence that this supplement produces the same event reduction.
Larger Studies Must Test Outcomes
The researchers say larger studies are needed to investigate how the supplement may affect vascular function and whether biomarker changes lead to longer-term health benefits. Further trials would need to clarify the results across a broader group of participants and assess effects over a longer period.
No specific follow-up trial or timeline is identified in the supplied report. Until further evidence is available, the study supports a research question about vascular markers rather than a conclusion that the supplement prevents cardiovascular disease.
Key Questions
What did the trial find?
Compared with placebo, participants taking NOVOS Core showed favorable changes in endothelial function, arterial stiffness and systolic blood pressure after six months. Researchers also reported changes in some measures within an hour of the first dose.
How many people took part?
The trial included 61 participants: 33 received the supplement and 28 received a placebo. Both groups were asked to take their assigned product daily for six months.
Did the study show that the supplement prevents heart attacks or strokes?
No. The trial assessed vascular biomarkers and was not designed to measure heart attacks, strokes or other clinical outcomes. It therefore cannot establish that the supplement prevents cardiovascular disease.
Did cholesterol levels change?
The report says blood tests found no significant changes in cholesterol or other blood lipids. The researchers said the vascular-marker changes were not explained by lipid lowering.
What further evidence is needed?
The study authors say larger, longer-term research is needed to examine the mechanisms and determine whether the marker changes lead to meaningful health benefits.
Source: news-medical.net
![[Comment] Could enpatoran add to our therapeutic toolbox in SLE?](https://breatheatlas.com/wp-content/uploads/2026/05/comment-could-enpatoran-add-to-our-therapeutic-toolbox-in-sle-featured-560x300.jpg)
